loader2
Login Open ICICI 3-in-1 Account
  • Text Size
  • Text to Speech
  • Color Contrast
  • Pause Animations
Open ICICI 3-in-1 Account

Indoco Remedies Results: Latest Quarterly Results & Analysis

Open Free Trading Account Online with ICICIDIRECT
+91
Indoco Remedies Ltd. 07 May 2026 13:03 PM
Result PDF

Q4FY26 & FY26 Result Announced for Indoco Remedies Ltd.

Pharmaceuticals company Indoco Remedies announced Q4FY26 & FY26 results

Consolidated Financial Highlights:

  • Total Income: The total income for Q4FY26 stood at Rs 47,557 lakh, representing a QoQ growth of 6.55% from Rs 44,634 lakh in Q3FY26 and a YoY increase of 21.25% from Rs 39,223 lakh in Q4FY25. For FY26, total income was Rs 1,84,865 lakh, compared to Rs 1,67,037 lakh in FY25, a growth of 10.67%.
  • Revenue from Operations: Revenue for Q4FY26 was Rs 45,590 lakh, up 4.96% QoQ from Rs 43,434 lakh and up 18.76% YoY from Rs 38,389 lakh. The annual revenue for FY26 reached Rs 1,79,294 lakh, showing an increase of 9.24% from Rs 1,64,129 lakh in FY25.
  • Net Profit / Loss: The company reported a consolidated net loss of Rs 2,368 lakh for Q4FY26, an improvement compared to a loss of Rs 2,945 lakh in Q3FY26 and a loss of Rs 4,134 lakh in Q4FY25. For FY26, the net loss widened to Rs 9,870 lakh from a loss of Rs 7,795 lakh in FY25.
  • Earnings Per Share (EPS): Basic and Diluted EPS for Q4FY26 was Rs (2.57) and Rs (2.56) respectively. For FY26, the basic EPS stood at Rs (10.70).

Standalone Financial Highlights:

  • Total Income: Standalone total income for Q4FY26 was Rs 45,948 lakh, registering a QoQ increase of 12.71% from Rs 40,768 lakh and a YoY increase of 29.89% from Rs 35,375 lakh. The annual standalone total income for FY26 was Rs 1,71,571 lakh, up from Rs 1,53,667 lakh in FY25.
  • Revenue from Operations: Standalone revenue for Q4FY26 stood at Rs 42,906 lakh, reflecting a growth of 10.14% QoQ from Rs 38,957 lakh and 25.80% YoY from Rs 34,107 lakh. Annual revenue for FY26 was Rs 1,63,354 lakh, a growth of 9.28% over Rs 1,49,478 lakh in FY25.
  • Net Profit / Loss: The standalone result for Q4FY26 showed a turnaround with a net profit of Rs 2,735 lakh, compared to a net loss of Rs 2,000 lakh in Q3FY26 and a net loss of Rs 2,624 lakh in Q4FY25. However, For FY26, the company reported a net loss of Rs 566 lakh, which was lower than the loss of Rs 873 lakh in FY25.
  • Earnings Per Share (EPS): Basic and Diluted EPS for Q4FY26 was Rs 2.96. For FY26, basic and diluted EPS was Rs (0.61).

Business Highlights:

  • Segment Performance: The company has only one primary reportable segment of activity, namely, Pharmaceuticals.
  • Geographical Performance:
    • India: Revenue from the Indian market for FY26 was Rs 89,413 lakh, compared to Rs 91,598 lakh in FY25.
    • Outside India: Revenue from international markets for FY26 grew significantly to Rs 73,941 lakh, compared to Rs 57,880 lakh in FY25.
  • Dividend: The Board of Directors has recommended a dividend of Rs 0.20 per equity share on a face value of Rs 2/- for the FY26.
  • Exceptional Items: Exceptional items for FY26 included a consideration of Rs 346 lakh received for granting license rights to trademarks, a loss of Rs 213 lakh on sale and leaseback of non-current assets, and an impact of Rs 427 lakh (consolidated) / Rs 419 lakh (standalone) due to the implementation of the New Labour Codes.
  • Labour Code Impact: The implementation of the four New Labour Codes resulted in an increase in gratuity liability and leave liability due to a change in the definition of "wages."
  • International Presence: The company operates 10 manufacturing facilities (6 for Finished Dosage Forms and 4 for APIs) and maintains a presence in various therapeutic segments, including Gastro-intestinal, Respiratory, Anti-Infectives, and Cardiovascular.

Aditi Panandikar, Managing Director, Indoco Remedies, said: “Revenue growth for the quarter and year was mainly driven by a good performance in the International Formulations Business, supported by a steady growth in the API & Services Businesses.”

Result PDF

Result PDF

Pharmaceuticals company Indoco Remedies announced Q3FY26 results

  • Revenues are Rs 3,896 million, as against Rs 3,649 million, in Q3FY25, registering a 7% revenue growth.
  • EBIDTA for the quarter is at Rs 259 million, compared to Rs 201 million in Q3FY25, registering a 29% growth.

Aditi Panandikar, Managing Director, Indoco Remedies, said: “The revenue growth in this quarter is mainly due to the Export Formulations business and API business.”

Result PDF

Pharmaceuticals company Indoco Remedies announced Q2FY26 results

  • Revenues of Rs 4,293 million, as against Rs 3,946 million, in Q2FY25, registering an 8.8 % revenue growth.
  • EBIDTA for the quarter is at Rs 534 million, compared to Rs 529 million in Q2FY25.
  • PBT: Rs 97.6 million compared to Rs 173.8 million during Q2FY25.
  • PAT: Rs 150.5 million compared to Rs 127.9 million during Q2FY25.

Aditi Panandikar, Managing Director, Indoco Remedies, said: “International formulation and API businesses had a good growth this quarter. The India formulation business performance was impacted due to revision in the GST rates. We are confident of regaining momentum in the coming quarters.”

Result PDF

Pharmaceuticals company Indoco Remedies announced Q1FY26 results

  • Revenues of Indoco Remedies are at Rs 3,838 million, as against Rs 3,411 million, in previous quarter, registering 12.5% revenue growth.
  • EBIDTA for the quarter is at Rs 148 million, compared to Rs 35 million in the previous quarter.

Aditi Panandikar, Managing Director, Indoco Remedies, said: “Our 12.5% revenue growth this quarter over last quarter reflects the resilience of our teams, operational excellence and robust strategy. We are confident of sustaining this momentum and making a turnaround going ahead.”

Result PDF

Pharmaceuticals company Indoco Remedies announced Q4FY25 & FY25 results

Q4FY25 Financial Highlights:

  • During the fourth quarter of FY 2024-25, revenues of Indoco Remedies are at Rs 3,411 million, as against Rs 4,351 million, same quarter last year.
  • EBIDTA for the quarter is at Rs 35 million, compared to Rs 574 million, same quarter last year.

FY25 Financial Highlights:

  • For the year, revenues are at Rs 14,948 million, as against Rs 17,620 million, same period last year. EBIDTA to net sales for the period is 8.6 % at Rs 1,280 million, compared to 14.6 % at Rs 2,580 million, same period last year.
  • Profit After Tax are at Rs -87 million, compared to Rs 1,166 million, same period last year.

Commenting on the results, Aditi Panandikar, Managing Director, Indoco Remedies said, “While this has been a challenging year for Indoco, there are several optimistic triggers which gives us confidence for a better future, both in the short as well as long term.”

Result PDF

Pharmaceuticals company Indoco Remedies announced Q3FY25 results

  • Revenue of Indoco Remedies is at Rs 3,649 million, as against Rs 4,484 million, Q3FY24.
  • EBIDTA to net sales for the quarter is at Rs 201 million, compared to Rs 653 million, Q3FY24.

Aditi Panandikar, Managing Director, Indoco Remedies, said: “Domestic Formulation Business continued to contribute in revenue growth, while the Export Formulation Business has been impacted by supply constraints from our sites that underwent planned shutdowns for enhancement of capacities and productivity.”

Result PDF

Pharmaceuticals company Indoco Remedies announced Q2FY25 results

  • Revenues: Rs 3,946 million, as against Rs 4,652 million, Q2FY24.
  • EBIDTA: is 13.4 % at Rs 529 million, compared to 15.6% at Rs 724 million, Q2FY24
  • Profit After Tax: 3.2 % at Rs 128 million, compared to 7.1% at Rs 331 million, Q2FY24.

Aditi Panandikar, Managing Director, Indoco Remedies said: “While a good performance by our Domestic Formulation business helped grow revenues, supply constraints have impacted the performance of the International Formulation business. Some of the sites supplying to US and Europe are under structured shutdowns to increase efficiency.”

Result PDF

Pharmaceuticals company Indoco Remedies announced Q1FY25 results:

  • During Q1FY25, revenues of Indoco Remedies are at Rs 3,942 million, as against Rs 4,132 million, same quarter last year.
  • EBIDTA to net sales for the quarter is 13.1% at Rs 516 million, compared to 15.2% at Rs 629 million, same quarter last year.
  • Profit After Tax to net sales is 3.8% at Rs 150 million, compared to 6.3% at Rs 259 million, same quarter last year.

Commenting on the results, Aditi Panandikar, Managing Director, Indoco Remedies said, “From licensing out products to front-ending in the US and from a 95% ethically driven domestic business, to selectively chosen products in OTC business, we are undergoing significant strategic transitions at Indoco. Our performance this quarter is reflective of these various strategic moves and I am confident that these will give Indoco a major gain in the long term.”

Result PDF

Pharmaceuticals company Indoco Remedies announced Q4FY24 & FY24 results:

Q4FY24 Financial Highlights:

  • During the Q4FY24, revenues of Indoco Remedies grew by 1.7% at Rs 4,351 million, as against Rs 4,280 million, same quarter last year.
  • EBIDTA to net sales for the quarter is 13.2% at Rs 574 million, compared to 15.0% at Rs 642 million, same quarter last year.
  • Profit After Tax to net sales is 8.6% at Rs 376 million, compared to 5.9% at Rs 254 million, same quarter last year.

FY24 Financial Highlights:

  • For the year, revenues grew by 7.6% at Rs 17,619 million, as against Rs 16,381 million, same period last year.
  • EBIDTA to net sales for the period is 14.6% at Rs 2,580 million, compared to 17.4% at Rs 2,849 million, same period last year.
  • Profit After Tax to net sales is 6.6% at Rs 1,166 million, compared to 8.6% at Rs 1,414 million, same period last year.

Commenting on the results, Aditi Panandikar, Managing Director, Indoco Remedies Ltd. said, “Indoco is set to take a big leap based on the various strategic decisions taken during this year. We are optimistic to improve our performance in the coming quarters.”

Result PDF

Pharmaceuticals firm Indoco Remedies announced Q3FY24 results:

Q3FY24

  • Revenue:
    Rs 4,484 million (growth of 9.2% compared to Rs 4,106 million in Q3 of the previous year)
  • EBIDTA:
    Rs 653 million, representing 14.6% of net sales (compared to Rs 617 million or 15.0% of net sales in Q3 of the previous year)
  • Profit After Tax:
    Rs 282 million (before exceptional item), which is comparable to the profit of Rs 279 million reported in the same quarter last year

9MFY24 (Apr-Dec)

  • Revenue:
    Rs 13,268 million (9.6% increase from Rs 12,101 million in the same period last year)
  • EBIDTA:
    Rs 2,006 million, 15.1% of net sales (against Rs 2,207 million, 18.2% of net sales in the previous year)
  • Profit After Tax:
    Rs 873 million (before exceptional item), 6.6% of net sales (compared to 9.6% or Rs 1,160 million in the same period last year)

Aditi Panandikar, Managing Director of Indoco Remedies Ltd., stated: "Our Q3 performance is primarily driven by International business particularly US and Emerging Markets, API business and steady performance by India business."

 

 

Result PDF

Trending News

Royal Enfield Slates ₹2,500 Cr Greenfield Unit in AP; CapEx to Boost Global Mid-Size Bike Growth

In a press release, Royal Enfield has announced plans for a major manufacturing expansion with the proposed acquisition of land in Tada, near Tirupati in Andhra Pradesh, for a new greenfield facility. 

Published on 19-May-2026 09:07

Happiest Minds: GenAI Entry Structurally Positive; Platform Shifts to Drive Sustained IT Growth

Happiest Minds Technologies stated that the recent entry of GenAI platform providers such as OpenAI (US$ 4 bn fund raise for The Deployment Company) and Anthropic ($1.5 billion joint venture) into enterprise services is structurally positive for IT services firms and will accelerate AI adoption rather than disrupt the sector. 

Published on 19-May-2026 09:06

Tata Consumer Q4: New-Age Channels Fuel 41% India Sales; Tata Sampann Hits ₹1,500 Cr

As per FY26 annual report, Tata Consumer Products (TCPL) highlighted a strong long-term growth outlook for India, supported by favourable demographics, rising disposable incomes and increasing health & wellness consumption trends. 

Published on 19-May-2026 09:05

Rishabh Instruments Q4 Net Profit Triples to ₹20 Cr; EBITDA Surges 106% on Turnaround

Rishabh Instruments reported a healthy operational performance in Q4FY26 with consolidated revenue growing 9.3% YoY to ₹205 crore, while EBITDA surged 106% YoY to ₹33.3 crore led by improved product mix, operating leverage and turnaround in the HPDC business. 

Published on 19-May-2026 09:04

Timken India Q4 Revenue Jumps 14.5% to ₹1,090 Cr; Net Profit Drops 16.8% On Higher Taxes

Timken India Limited reported Q4FY26 revenue growth of 14.5% YoY to ₹1,090 crore, driven by healthy demand across industrial and rail segments. 

Published on 19-May-2026 09:03

Astral Q4 profit jumps 19% to ₹213 Cr, revenue grows 24% to ₹2,089 Cr

Astral Limited reported strong Q4FY26 performance with consolidated revenue rising 24% YoY to ₹ 2,089 crore, driven by robust plumbing volume growth of 24% (84,041 MT). 

Published on 19-May-2026 09:02

Disclaimer – I ICICI Securities Ltd. ( I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is acting as a distributor to solicit bond related products. All disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein mentioned are solely for informational and educational purpose.
Download App

Download Our App

Get it on google Play Store Download on the App Store
market app